课题基金 / 基金详情

Structural mechanisms of regulation and assembly in the nephronophthisis INVS-NPHP3-NEK8-ANKS6 module

Structural mechanisms of regulation and assembly in the nephronophthisis INVS-NPHP3-NEK8-ANKS6 module
肾结核INVS-NPHP3-NEK8-ANKS6模块调节和组装的结构机制
批准号:
MR/L017032/1
负责人:
Richard Bayliss
金额:
$48.3万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2014
资助国家:
英国
项目状态:
已结题
起止时间:
2014 至 --

项目摘要

项目成果

Richard Bayliss的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Cystic kidney diseases represent a major health burden for which there are few effective treatments. Yet we are far from understanding the cell biology behind these diseases. Here, we propose to study the regulation and function of proteins that are mutated in nephronophthisis, an inherited childhood cystic kidney disease. These proteins coordinate signals received by developing kidney cells at antenna-like structures on the cell surface, called primary cilia. Defective signalling leads to loss of cell division control and cyst formation. Our aim is to provide new insights into cystic kidney disease mechanisms that will ultimately lead to new therapies.We will concentrate our efforts principally on two proteins, NEK8 and INVS. NEK8 belongs to a family of enzymes called protein kinases. These modify other proteins to modulate their functions, and are often found in signalling pathways that pass information from the cell surface to the cell nucleus so that cells may respond to their environment. The activity of protein kinases, that is to say the efficiency with which they modify other proteins, is strictly controlled. Protein kinases and other proteins that control them are very commonly mutated in diseases. The mutations result in uncontrolled kinase activity so that signalling pathways malfunction: they might pass signals to the nucleus when they should not, or they might block signals that ought to be passed on. We discovered that INVS controls the activity of NEK8, and we mapped the part of INVS responsible down to a region of the protein that is usually disrupted in patients that have INVS mutations. In many patients, it seems that disease is caused by missing just this region of INVS. In the first part of this project, we will investigate how INVS controls the activity of NEK8. To simplify matters, we will study just the two proteins in isolation. Crystallography will be used to produce atomic-resolution models of NEK8, both alone and associated with INVS, to show how its activity is controlled in the maximum possible detail. Crystallography produces detailed but static models. So we will apply advanced biochemical methods that enable us to track the activity of NEK8 over time under a number of different experimental conditions. This will provide us with a detailed understanding of what effects INVS has on NEK8, and what is therefore lacking in patients that have mutations in INVS.In the second part of this project, we will broaden our study to encompass two further proteins that are associated with NEK8 and INVS and that are also mutated in cystic kidney disease. We will investigate whether and how these proteins associate and how these interactions relate to the activity of NEK8. Finally, we will examine mutations in these proteins that were found in cystic kidney disease patients, to discover their effects on the interactions between proteins. Although many of the genes involved in cystic kidney disease are known, we have very little insight into how mutations in these genes cause disease. In this project, we will explore the idea that these mutations disrupt the interactions between a group of proteins, leading to loss of control of NEK8 activity. These insights will influence the way we think about signalling in the cilia, and how this goes awry in a range of associated diseases. We will produce a detailed model to explain how NEK8 activity is controlled by INVS and generate the first chemical compounds that block NEK8 activity. Our work will provide the basis for strategies to rescue ciliary signalling in cells with mutations in NEK8, INVS and interacting proteins. If successful, this might eventually lead to new therapies for patients.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/ncomms9771
发表时间: 2015-11-02
期刊: Nature communications
影响因子: 16.6
作者: [Haq T, Richards MW, Burgess SG, Gallego P, Yeoh S, O'Regan L, Reverter D, Roig J, Fry AM, Bayliss R]
通讯作者: Bayliss R
DOI: 10.3389/fcell.2017.00102
发表时间: 2017
期刊: Frontiers in cell and developmental biology
影响因子: 5.5
作者: [Fry AM, Bayliss R, Roig J]
通讯作者: Roig J
DOI: 10.1016/j.bbapap.2015.04.025
发表时间: 2015-10-01
期刊: BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
影响因子: 3.2
作者: [Bayliss, Richard, Haq, Tamanna, Yeoh, Sharon]
通讯作者: Yeoh, Sharon
DOI: 10.1042/bcj20200128
发表时间: 2020-04-01
期刊: BIOCHEMICAL JOURNAL
影响因子: 4.1
作者: [Byrne, Matthew J., Nasir, Nazia, Bayliss, Richard]
通讯作者: Bayliss, Richard
Understanding and targeting oncogenic biomolecular condensates of ALK kinase
  • 批准号:
    MR/X008673/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $101.02万
  • 财政年份:
    2023
  • 负责人:
    Richard Bayliss
  • 依托单位:
The structural basis of transcription factor 3C recruitment by N-myc
  • 批准号:
    MR/V029975/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $93.32万
  • 财政年份:
    2021
  • 负责人:
    Richard Bayliss
  • 依托单位:
Phosphodependent helix switches in cellular signalling
  • 批准号:
    BB/S00730X/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $107.85万
  • 财政年份:
    2019
  • 负责人:
    Richard Bayliss
  • 依托单位:
Assembly of the mitotic inter-microtubule bridge complex clathrin-TACC3-ch-TOG: a hybrid structural biology approach
  • 批准号:
    BB/L023113/2
  • 项目类别:
    Research Grant
  • 资助金额:
    $44.06万
  • 财政年份:
    2016
  • 负责人:
    Richard Bayliss
  • 依托单位:
国内基金
海外基金
Exploring the Intrinsic Mechanisms of CEO Turnover and Market
  • 批准号:
    --
  • 项目类别:
    外国学者研究基金
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    HAOFEI Z
  • 依托单位:
Exploring the Intrinsic Mechanisms of CEO Turnover and Market Reaction: An Explanation Based on Information Asymmetry
  • 批准号:
    W2433169
  • 项目类别:
    外国学者研究基金项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    HAOFEI ZHANG
  • 依托单位:
Erk1/2/CREB/BDNF通路在CSF1R相关性白质脑病致病机制中的作用研究
  • 批准号:
    82371255
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    曹立
  • 依托单位:
Foxc2介导Syap1/Akt信号通路调控破骨/成骨细胞分化促进颞下颌关节骨关节炎的机制研究
  • 批准号:
    82370979
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    张善勇
  • 依托单位: